Clinical diagnosis of CRPC is based on a significant increase in tumor burden or metastasis detected using computed tomography (CT) scans, bone scintigraphy or magnetic resonance imaging (MRI), and/or rising serum prostate-specific antigen (PSA) levels [2]. This evidence concerns the gene KLK3 and neoplasm.